Aurigene in licensing agreement with Debiopharm

Bangalore, India and Lausanne, Switzerland, November 24, 2008 – Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies

Aurigene Announced Significant Milestone in a Collaboration Program

Aurigene has announced the achievement of a significant pre-clinical milestone in a Discovery collaboration with Novartis Pharma AG, Switzerland. Aurigene, which entered into a collaboration with Novartis in October, 2007,

Aurigene Announces Completion of Purchase of Discovery Research Facility in Hyderabad

Aurigene has completed the purchase of an additional site in Hyderabad with a fully integrated infrastructure and complement of high-quality and experienced scientific staff for Drug Discovery. This facility, along

Aurigene and Pcovery in pact to undertake anti-fungal drug discovery

Aurigene Discovery Technologies Ltd. today announced a drug discovery deal with Danish start-up Pcovery. Under the terms of this agreement, Aurigene and Pcovery will work collaboratively to progress early hits

Debiopharm Group™ and Aurigene nominate development candidate Debio 0617, a novel inhibitor of an undisclosed oncology pathway

Lausanne, Switzerland and Bangalore, India September 8, 2010 –Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway

Lausanne, Switzerland, and Bangalore, India, April 14, 2011 – Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies